MEDICINA
Departamento
Seoul St. Mary's Hospital
Seúl, Corea del SurPublicaciones en colaboración con investigadores/as de Seoul St. Mary's Hospital (5)
2021
-
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
Annals of Hematology, Vol. 100, Núm. 4, pp. 1065-1077
2020
-
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. 509-518
-
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk
Journal of Hematology and Oncology, Vol. 13, Núm. 1
2018
-
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR
Haematologica, Vol. 103, Núm. 12, pp. 2079-2087
2014
-
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Blood, Vol. 123, Núm. 26, pp. 4136-4142